CoChat

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., Gallwitz, B., PREFER Study Group · 2009 · Diabetes, Obesity and Metabolism
Cited by 149

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: Insulin analogues are widely used but few data exist comparing different analogue regimens. We compared two such regimens in type 2 diabetes mellitus (T2DM) uncontrolled by oral antidiabetic agents (OADs) with or without basal insulin. Methods: In a 26‐week multinational, multicentre, randomized treat‐to‐target trial, OADs were discontinued and subjects randomized to analogue basal–bolus therapy (insulin detemir once daily and insulin aspart mealtimes) or biphasic insulin aspart 30 (30% rapid‐acting insulin aspart), twice daily. Insulin was titrated to targets for fasting, predinner and postprandial plasma glucose (PG), as appropriate. Results: Of 719 subjects, 92% completed the study; 58% achieved haemoglobin fraction A 1c (HbA 1c ) ≤7.0%, with reductions of 1.56% (to 6.96%) with basal–bolus therapy and 1.23% (to 7.17%) with biphasic insulin aspart. Reduction with basal–bolus therapy was superior in the overall population by 0.23% (p = 0.0052), with no difference between regimens in insulin‐naive patients. Major hypoglycaemia occurred in five basal–bolus patients (0.9%) and in no patients with biphasic insulin aspart. Incidence of minor hypoglycaemia was similar in both groups. All insulin doses increased during titration, with increase in lunchtime insulin aspart dose and equal distribution of breakfast and dinner biphasic insulin aspart doses. Insulin detemir remained once daily in 87% of patients. Conclusions: Modern insulin analogue regimens, adjusted to PG targets, enable a majority of people with T2DM to reach HbA 1c ≤7.0% after failure of OADs and OAD‐basal insulin therapy. Insulin‐treated patients may benefit more from transfer to analogue basal–bolus therapy, while insulin‐naive individuals benefit equally well from the more convenient biphasic analogue regimen.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00915.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 149

Metadata

Authors
Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., Gallwitz, B., & PREFER Study Group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-12-22
Volume
11
Issue
1
Pages
45-52
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1977107344
Cited by
149
References
8
FWCI
11.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00915.x
The paper
Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., Gallwitz, B., & PREFER Study Group. (2009). Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00915.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.